CN-115785245-B - Galectin 10 crystal, antibody IgY prepared from same and pharmaceutical preparation

Abstract

The invention provides a galectin 10 (Gal 10) crystal, a preparation method thereof, and an antibody IgY and a pharmaceutical preparation prepared by the same, belonging to the technical field of medicines. The egg yolk neutralizing antibody IgY which can dissolve Gal10 crystals is prepared by taking the galectin 10 crystals as antigens, has the effects of improving rhinitis or asthma of patients, preventing and treating the rhinitis and the asthma, is safe and free of side effects after long-term use, durable in curative effect and free of drug resistance, provides a safe, simple, convenient, sanitary, effective and economic personalized treatment mode for preventing and treating the rhinitis and the asthma, and has higher market value.

Inventors

• ZHAO KAI
• ZHAO BINAN
• Zu Liujing
• SHI BIN
• ZHAO HUANZHEN
• ZHAO YUEQI

Assignees

• 上海博满生物科技有限公司

Dates

Publication Date

20260512

Application Date

20220718

Claims (5)

1. 1. An antibody IgY for dissolving galectin 10 crystals, characterized in that the preparation method comprises the following steps: The method comprises the steps of taking a galectin 10 crystal as an antigen, and immunizing an egg-laying hen, wherein the amino acid sequence of the galectin 10 crystal is shown as SEQ ID NO.1, the concentration of the galectin 10 crystal in the antigen is 50-100 mug/ml, the method for immunizing the egg-laying hen is divided into 3 times, two times of immunization are separated by 28-30 d, a 3-point immunization method is adopted for each immunization, and the immunization dose of the antigen at each immunization site is 30-50 mug/hen; Collecting eggs at intervals of 14 days after the initial immunization for 3 times and the third immunization, removing the lecithin and other deposits of the egg yolk aqueous solution under an acidic condition, and sequentially passing the obtained supernatant through a filtering membrane with molecular weight of 0.45 mu m and 50000 to obtain the antibody IgY; The acidic condition is that the pH value of the egg yolk aqueous solution is 4.8-5.5; the method for removing the sediment of the egg yolk aqueous solution comprises centrifugation, wherein the rotation speed of the centrifugation is 7500-8500 rpm, and the centrifugation time is 15-25 min.
2. 2. A medicament for preventing and treating rhinitis and/or asthma, which comprises the antibody IgY of claim 1 and pharmaceutically acceptable auxiliary materials.
3. 3. The medicament according to claim 2, wherein the medicament is in the form of a spray, and the spray comprises the following components in percentage by mass: 0.1-0.4% of antibody IgY, 0.1-0.9% of lysozyme, 1-10% of glycerol, 0.04-0.1% of chlorhexidine gluconate and 88.6-98.76% of distilled water.
4. 4. The medicament according to claim 2, wherein the medicament is in the form of a nebulizer; The atomizing agent comprises the following components in percentage by mass: 0.1-0.4% of antibody IgY, 0.1-0.9% of lysozyme, 0.005-0.02% of nisin, 1-10% of glycerol, 0.04-0.1% of chlorhexidine gluconate and 88.58-98.755% of distilled water.
5. 5. Use of the antibody IgY of claim 1 for the preparation of a medicament for the prevention and treatment of rhinitis and/or asthma.

Description

Galectin 10 crystal, antibody IgY prepared from same and pharmaceutical preparation Technical Field The invention belongs to the technical field of medicines, and particularly relates to a galectin 10 crystal, an antibody IgY prepared from the same and a pharmaceutical preparation. Background Rhinitis is a kind of nasal cavity inflammation caused by virus, bacteria, allergen, various physical and chemical factors and some systemic diseases. The main pathological changes of rhinitis are nasal mucosa congestion, swelling, exudation, hyperplasia, atrophy or necrosis. Allergic rhinitis (commonly known as allergic rhinitis) is a chronic disease with high incidence, long course of disease and easy recurrent attacks. 70% of severe allergic rhinitis can affect sleep, 94% of severe allergic rhinitis can affect life and work, the influence on life quality even exceeds serious diseases such as hypertension, diabetes and the like, and the allergic rhinitis is possibly combined with various diseases such as otitis media, nasosinusitis, nasal polyp, asthma and the like, so that the health hazard is more serious. And also can worsen the formation of nasopharyngeal carcinoma due to allergic rhinitis. Therefore, the prevention and treatment of rhinitis should be paid attention to. At present, hormone, antihistamine and leukotriene resisting treatment are mostly adopted clinically, but side effects cannot be ignored. The drug resistance is easy to generate after repeated use, and the long-term use of hormone can influence the development of children and teenagers. Asthma is a heterogeneous disease characterized by chronic inflammation of the airways involving various cells (e.g., eosinophils, mast cells, T lymphocytes, neutrophils, airway epithelial cells, etc.) and cellular components, which is associated with airway hyperresponsiveness, and which is often associated with extensive and variable reversible expiratory airflow limitation, resulting in recurrent wheezing, shortness of breath, chest distress, and/or cough, and the like, with intensity varying over time. Often at night and/or early morning, asthma such as untimely diagnosis and treatment may produce irreversible airway constriction and airway remodeling with prolonged disease course. Current asthma treatment is generally divided into four courses depending on the severity of the disease (1) long-term anti-inflammatory treatment is the underlying treatment, most preferably inhalation of hormones. Commonly used inhaled drugs include beclomethasone (beclomethasone, BDP), budesonide, fluticasone, mometasone (momethasone) and the like, and the two drugs have stronger biological activity and longer lasting effect. It is usually required to take more than one week for regular inhalation to be effective. (2) The first drug to provide emergency relief from symptoms is an inhaled β2 agonist. Beta 2 agonists activate adenylate cyclase by mainly agonizing the beta 2 receptor of the respiratory tract, increasing the cyclic adenosine monophosphate (cAMP) content in the cells and decreasing free Ca, thereby relaxing bronchial smooth muscle, and are the first choice for controlling asthma attacks. (3) For those with unsatisfactory disease control after regular inhalation of hormone, it is advisable to add inhaled long-acting β2 agonist, slow-release theophylline or leukotriene regulator (combination), and also consider to increase the amount of inhaled hormone. (4) Patients with severe asthma can be considered as intensive therapy when they have repeated attacks over a long period of time after the above treatment. I.e. according to the treatment of severe asthma attacks, a large dosage of hormone is administered, and the hormone dosage is gradually reduced after the symptoms are completely controlled, the lung function is restored to the optimal level and the PEF fluctuation rate is normal for 2 to 4 days. Some patients can control the illness perfectly after the stage of intensive treatment. Therefore, the effective treatment approaches commonly used for rhinitis and asthma at present are hormone treatment, however, the hormone treatment has serious side effects, and the administration requirements of patients cannot be met. Disclosure of Invention In view of the above, an object of the present invention is to provide a galectin 10 crystal which is produced by recombinant expression in vitro and which can produce antibodies that solubilize galectin 10 crystals in animals. The invention also aims to provide an antibody IgY of the anti-galectin 10 crystal, which completely neutralizes inflammatory reaction caused by the galectin 10 crystal by dissolving the galectin 10 crystal, thereby achieving the purpose of treating asthma and rhinitis. The invention also aims to provide a medicine for preventing and treating rhinitis and asthma, which has the characteristics of safety, effectiveness and economy. The invention provides a galectin 10 crystal, and the amino acid sequence of the